-
3
-
-
63049115790
-
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup
-
Bookman M, Brady MF, McGuire WP et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup. J Clin Oncol 2009; 27: 1419-1425.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1419-1425
-
-
Bookman, M.1
Brady, M.F.2
McGuire, W.P.3
-
4
-
-
33847242677
-
A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer
-
Hess LM, Benham-Hutchins M, Herzog TJ et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 2007; 17: 561-570.
-
(2007)
Int J Gynecol Cancer
, vol.17
, pp. 561-570
-
-
Hess, L.M.1
Benham-Hutchins, M.2
Herzog, T.J.3
-
5
-
-
30044438368
-
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
-
Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Engl J Med 2006; 354: 34-43.
-
(2006)
New Engl J Med
, vol.354
, pp. 34-43
-
-
Armstrong, D.K.1
Bundy, B.2
Wenzel, L.3
-
6
-
-
77957684487
-
MRC OV05/EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
-
Rustin GJ, van der Burg ME, Griffin CL et al. MRC OV05/EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010; 376: 1155-1163.
-
(2010)
Lancet
, vol.376
, pp. 1155-1163
-
-
Rustin, G.J.1
van der Burg, M.E.2
Griffin, C.L.3
-
7
-
-
33644516543
-
Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range
-
Santillan A, Garg R, Zahurak ML et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 2005; 23: 9338-9343.
-
(2005)
J Clin Oncol
, vol.23
, pp. 9338-9343
-
-
Santillan, A.1
Garg, R.2
Zahurak, M.L.3
-
8
-
-
0037404173
-
Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation
-
Wilder JL, Pavlik E, Straughn JM et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol 2003; 89: 233-235.
-
(2003)
Gynecol Oncol
, vol.89
, pp. 233-235
-
-
Wilder, J.L.1
Pavlik, E.2
Straughn, J.M.3
-
9
-
-
77954017982
-
Commentary: CA125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease
-
Bast RC Jr. Commentary: CA125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 2010; 116: 2850-2853.
-
(2010)
Cancer
, vol.116
, pp. 2850-2853
-
-
Bast Jr., R.C.1
-
10
-
-
0037862963
-
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
-
Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106.
-
(2003)
Lancet
, vol.361
, pp. 2099-2106
-
-
Parmar, M.K.1
Ledermann, J.A.2
Colombo, N.3
-
11
-
-
79955447888
-
CA125 surveillance increases optimal respectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer
-
Fleming ND, Cass I, Walsh CS et al. CA125 surveillance increases optimal respectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 2011; 121: 249-252.
-
(2011)
Gynecol Oncol
, vol.121
, pp. 249-252
-
-
Fleming, N.D.1
Cass, I.2
Walsh, C.S.3
-
12
-
-
78651437988
-
Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease
-
Callahan R, Hurvitz S. Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease. Current Opinion Obstet Gynecol 2011; 23: 37-43.
-
(2011)
Current Opinion Obstet Gynecol
, vol.23
, pp. 37-43
-
-
Callahan, R.1
Hurvitz, S.2
-
13
-
-
79952022701
-
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors
-
Jabbour E, Cortes J, Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer 2011; 117: 897-906.
-
(2011)
Cancer
, vol.117
, pp. 897-906
-
-
Jabbour, E.1
Cortes, J.2
Kantarjian, H.3
-
14
-
-
79952476180
-
Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review
-
Essaf M, Cooper K. Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review. Int J Cancer 2011; 128: 2202-2214.
-
(2011)
Int J Cancer
, vol.128
, pp. 2202-2214
-
-
Essaf, M.1
Cooper, K.2
-
15
-
-
77958102568
-
Personalized medicine for non-small cell lung cancer
-
Mok TS, Zhou Q, Leung L et al. Personalized medicine for non-small cell lung cancer. Expert Rev Anticancer Ther 2010; 10: 1601-1611.
-
(2010)
Expert Rev Anticancer Ther
, vol.10
, pp. 1601-1611
-
-
Mok, T.S.1
Zhou, Q.2
Leung, L.3
-
16
-
-
81155137143
-
Personalized medicine in a phase I trials program: the M.D. Anderson initiative
-
Abstr CRA2500
-
Tsinmberidou AM. Personalized medicine in a phase I trials program: the M.D. Anderson initiative. J Clin Oncol 2011; 29(18S): 787s (Abstr CRA2500).
-
(2011)
J Clin Oncol
, vol.29
, Issue.18 S
-
-
Tsinmberidou, A.M.1
-
17
-
-
79957811258
-
STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis
-
Mehra K, Mehrad M, Ning G et al. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci 2011; 3: 625-634.
-
(2011)
Front Biosci
, vol.3
, pp. 625-634
-
-
Mehra, K.1
Mehrad, M.2
Ning, G.3
-
18
-
-
80051549633
-
Ovarian cancer. In Hong WK, Bast RC Jr, Hait W, et al. (eds), Holland-Frei Cancer Medicine, 8th edition
-
Berek JS, Friedlander ML, Bast RC Jr. Ovarian cancer. In Hong WK, Bast RC Jr, Hait W, et al. (eds), Holland-Frei Cancer Medicine, 8th edition. Shelton, CT: PMPH 2010; 1344-1375.
-
(2010)
Shelton, CT: PMPH
, pp. 1344-1375
-
-
Berek, J.S.1
Friedlander, M.L.2
Bast Jr., R.C.3
-
19
-
-
0026453635
-
Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation and X chromosome inactivation
-
Jacobs IJ, Kohler MF, Wiseman R et al. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation and X chromosome inactivation. J Natl Cancer Inst 1992; 84: 1793-1798.
-
(1992)
J Natl Cancer Inst
, vol.84
, pp. 1793-1798
-
-
Jacobs, I.J.1
Kohler, M.F.2
Wiseman, R.3
-
20
-
-
18344373769
-
Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract
-
Cheng W, Liu J, Yoshida H et al. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 2005; 11: 531-537.
-
(2005)
Nat Med
, vol.11
, pp. 531-537
-
-
Cheng, W.1
Liu, J.2
Yoshida, H.3
-
21
-
-
77649219639
-
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory
-
Kurman RJ, Shih IEM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433-443.
-
(2010)
Am J Surg Pathol
, vol.34
, pp. 433-443
-
-
Kurman, R.J.1
Shih, I.E.M.2
-
22
-
-
77957354624
-
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas
-
Wong KK, Tsang YT, Deavers MT et al. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol 2010; 177: 1611-1617.
-
(2010)
Am J Pathol
, vol.177
, pp. 1611-1617
-
-
Wong, K.K.1
Tsang, Y.T.2
Deavers, M.T.3
-
23
-
-
77957946398
-
ARID1A mutations in endometriosis-associated ovarian carcinomas
-
Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543.
-
(2010)
N Engl J Med
, vol.363
, pp. 1532-1543
-
-
Wiegand, K.C.1
Shah, S.P.2
Al-Agha, O.M.3
-
24
-
-
79952568603
-
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas
-
McConechy MK, Anglesio MS, Kalloger SE et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol 2011; 223: 567-573.
-
(2011)
J Pathol
, vol.223
, pp. 567-573
-
-
McConechy, M.K.1
Anglesio, M.S.2
Kalloger, S.E.3
-
25
-
-
80052583874
-
The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma
-
King ER, Zu Z, Tsang YT et al. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol Oncol 2011; 123: 13-18.
-
(2011)
Gynecol Oncol
, vol.123
, pp. 13-18
-
-
King, E.R.1
Zu, Z.2
Tsang, Y.T.3
-
26
-
-
33746646758
-
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia
-
Kojima K, Konopleva M, McQueen T et al. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006; 108: 993-1000.
-
(2006)
Blood
, vol.108
, pp. 993-1000
-
-
Kojima, K.1
Konopleva, M.2
McQueen, T.3
-
27
-
-
79959838081
-
The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma
-
The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
-
(2011)
Nature
, vol.474
, pp. 609-615
-
-
-
28
-
-
67649440886
-
The biology of ovarian cancer: new opportunities for translation
-
Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nature Rev Cancer 2009; 9: 415-428.
-
(2009)
Nature Rev Cancer
, vol.9
, pp. 415-428
-
-
Bast Jr., R.C.1
Hennessy, B.2
Mills, G.B.3
-
29
-
-
52649085237
-
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
-
Tothill RW, Tinker AV, George J et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-5208.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 5198-5208
-
-
Tothill, R.W.1
Tinker, A.V.2
George, J.3
-
30
-
-
77955911553
-
Personalizing therapy for ovarian cancer: BRCAness and beyond
-
Bast RC, Mills GB. Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 2010; 28: 3545-3548.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3545-3548
-
-
Bast, R.C.1
Mills, G.B.2
-
31
-
-
0033986363
-
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study
-
Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000; 18: 106-115.
-
(2000)
J Clin Oncol
, vol.18
, pp. 106-115
-
-
Muggia, F.M.1
Braly, P.S.2
Brady, M.F.3
-
32
-
-
80052245462
-
Modulating microtubule stability enhances the cytotoxic response of cancer cells to paclitaxel
-
Ahmed AA, Wang X, Lu Z et al. Modulating microtubule stability enhances the cytotoxic response of cancer cells to paclitaxel. Cancer Res 2011; 71: 5806-5817.
-
(2011)
Cancer Res
, vol.71
, pp. 5806-5817
-
-
Ahmed, A.A.1
Wang, X.2
Lu, Z.3
-
33
-
-
77955530763
-
SIK2 is a centrosome kinase required for bipolar spindle formation that provides a potential target for therapy in ovarian cancer
-
Ahmed AA, Lu Z, Jennings NB et al. SIK2 is a centrosome kinase required for bipolar spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 2010; 18: 109-121.
-
(2010)
Cancer Cell
, vol.18
, pp. 109-121
-
-
Ahmed, A.A.1
Lu, Z.2
Jennings, N.B.3
-
34
-
-
77957336317
-
Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation
-
Whitehurst AW, Xie Y, Purinton SC et al. Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation. Cancer Res 2010; 70: 7652-7661.
-
(2010)
Cancer Res
, vol.70
, pp. 7652-7661
-
-
Whitehurst, A.W.1
Xie, Y.2
Purinton, S.C.3
-
35
-
-
66649118310
-
Therapeutic targeting of ATP7B in ovarian carcinoma
-
Mangala LS, Zuzel V, Schmandt R et al. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 2009; 15: 3770-3780.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3770-3780
-
-
Mangala, L.S.1
Zuzel, V.2
Schmandt, R.3
-
36
-
-
78650624101
-
RNA interference in the clinic: challenges and future directions
-
Pecot CV, Calin GA, Coleman RL et al. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011; 11: 59-67.
-
(2011)
Nat Rev Cancer
, vol.11
, pp. 59-67
-
-
Pecot, C.V.1
Calin, G.A.2
Coleman, R.L.3
-
37
-
-
77956648238
-
Targeted trials in ovarian cancer
-
Ledermann JA, Raja FA. Targeted trials in ovarian cancer. Gynecol Oncol 2010; 119: 151-156.
-
(2010)
Gynecol Oncol
, vol.119
, pp. 151-156
-
-
Ledermann, J.A.1
Raja, F.A.2
-
38
-
-
79953208074
-
Bevacizumab in the treatment of ovarian cancer
-
Eskander RN, Randall LM. Bevacizumab in the treatment of ovarian cancer. Biologics 2011; 5: 1-5.
-
(2011)
Biologics
, vol.5
, pp. 1-5
-
-
Eskander, R.N.1
Randall, L.M.2
-
39
-
-
13044283423
-
NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas
-
Yu Y, Xu F, Fang X et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 1999; 96: 214-219.
-
(1999)
Proc Natl Acad Sci USA
, vol.96
, pp. 214-219
-
-
Yu, Y.1
Xu, F.2
Fang, X.3
-
40
-
-
33744528546
-
Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers
-
Regulators and Effectors of Small GTPases. Part D. Ras Proteins
-
Yu Y, Luo R, Lu Z et al. Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. In Balch WE, Der C, Hall A (eds), Methods in Enzymology, Vol. 407: Regulators and Effectors of Small GTPases. Part D. Ras Proteins. 2006; 455-467.
-
(2006)
In Balch WE, Der C, Hall A (eds), Methods in Enzymology
, vol.407
, pp. 455-467
-
-
Yu, Y.1
Luo, R.2
Lu, Z.3
-
41
-
-
57449121645
-
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells
-
Lu Z, Luo RZ, Lu Y et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 2008; 118: 3917-3929.
-
(2008)
J Clin Invest
, vol.118
, pp. 3917-3929
-
-
Lu, Z.1
Luo, R.Z.2
Lu, Y.3
-
42
-
-
9144240441
-
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene
-
Qu X, Yu J, Bhagat G et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003; 112: 1809-1820.
-
(2003)
J Clin Invest
, vol.112
, pp. 1809-1820
-
-
Qu, X.1
Yu, J.2
Bhagat, G.3
-
43
-
-
0020559574
-
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer
-
Bast RC Jr, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New Engl J Med 1983; 309: 883-887.
-
(1983)
New Engl J Med
, vol.309
, pp. 883-887
-
-
Bast Jr., R.C.1
Klug, T.L.2
St John, E.3
-
44
-
-
0021842455
-
Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma
-
Bast RC Jr, Siegal FP, Runowicz C et al. Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol 1985; 22: 115-120.
-
(1985)
Gynecol Oncol
, vol.22
, pp. 115-120
-
-
Bast Jr., R.C.1
Siegal, F.P.2
Runowicz, C.3
-
45
-
-
63149087256
-
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
-
Menon U, Gentry-Maharaj A, Hallett R et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009; 10: 327-340.
-
(2009)
Lancet Oncol
, vol.10
, pp. 327-340
-
-
Menon, U.1
Gentry-Maharaj, A.2
Hallett, R.3
-
46
-
-
77954494547
-
A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA)
-
(Abstr 5003)
-
Lu KH, Skates S, Bevers T et al. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). Proc Am Soc Clin Oncol 2010: 28: (Abstr 5003).
-
(2010)
Proc Am Soc Clin Oncol
, vol.28
-
-
Lu, K.H.1
Skates, S.2
Bevers, T.3
-
47
-
-
27144489497
-
Potential markers that complement expression of CA 125 in epithelial ovarian cancer
-
Rosen D, Wang L, Atkinson JN et al. Potential markers that complement expression of CA 125 in epithelial ovarian cancer. Gynecol Oncol 2005; 99: 267-277.
-
(2005)
Gynecol Oncol
, vol.99
, pp. 267-277
-
-
Rosen, D.1
Wang, L.2
Atkinson, J.N.3
-
48
-
-
77952315345
-
Development of a multimarker assay for early detection of ovarian cancer
-
Yurkovetsky Z, Lomakin A, Skates S et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010; 28: 2159-2166.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2159-2166
-
-
Yurkovetsky, Z.1
Lomakin, A.2
Skates, S.3
|